167 related articles for article (PubMed ID: 7427980)
1. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
[No Abstract] [Full Text] [Related]
2. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
Andĕl M; Brodan V; Kucerová L; Brodanová M
Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
[No Abstract] [Full Text] [Related]
3. Early and late results of coronary artery bypass in patients with hyperlipoproteinemia.
Hanson EC; Levine FH; Adzick NS; Lees RS; Daggett WM; Austen WG; Buckley MJ
J Thorac Cardiovasc Surg; 1980 Mar; 79(3):372-80. PubMed ID: 6965512
[No Abstract] [Full Text] [Related]
4. [Plafibride treatment of hyperlipidemias type II and IV].
Soler J; Vinzia C; Gómez JM; Morató J
Med Clin (Barc); 1984 May; 82(19):840-2. PubMed ID: 6738212
[No Abstract] [Full Text] [Related]
5. [Gemfibrozil in the treatment of hyperlipoproteinemias].
Monova D; Petrova V; Belovezhdov N
Vutr Boles; 1991; 30(2):56-8. PubMed ID: 1891900
[TBL] [Abstract][Full Text] [Related]
6. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
Uccella R; Morenghi R; Agosti C; Saponati G
Artery; 1983; 11(5):400-12. PubMed ID: 6661043
[TBL] [Abstract][Full Text] [Related]
7. [Serum cholesterol and triglyceride levels in patients with type II hyperlipoproteinemia treated with probucol].
Markiewicz M; Rymar B; Horubała-Bielak G; Koziara Z
Wiad Lek; 1984 Oct; 37(19):1489-93. PubMed ID: 6528586
[No Abstract] [Full Text] [Related]
8. The influence of a no-sugar diet on the composition of VLDL-fraction in patients with idiopathic hyperlipoprotenemia of type IIb and IV.
Cybulska B; Naruszewicz M; Kłosiewicz-Latoszek L; Szostak WB; Chotkowska E
Mater Med Pol; 1980; 12(4):286-92. PubMed ID: 7266054
[No Abstract] [Full Text] [Related]
9. [Fatty acid metabolism in primary hyperlipoproteinemia (HLP) (author's transl)].
Reuter W
Dtsch Z Verdau Stoffwechselkr; 1979; 39(3):124-9. PubMed ID: 520271
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
[TBL] [Abstract][Full Text] [Related]
11. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
[No Abstract] [Full Text] [Related]
13. [The combination of psoriasis with different types of lipoproteinemias. 2. The characteristics of the dyslipoproteinemias caused by disorders in triacylglyceride transport in psoriasis].
Keshileva ZB; Kosukhin AB; Polevaia LG
Vestn Dermatol Venerol; 1990; (5):7-11. PubMed ID: 2402946
[TBL] [Abstract][Full Text] [Related]
14. [Subfractions of HDL cholesterol. Occurrence in hyperlipoproteinemia type IIa and IV].
Mertz DP; Thuilot G; Bürvenich K
Fortschr Med; 1986 Jul; 104(26):508-10. PubMed ID: 3744260
[No Abstract] [Full Text] [Related]
15. [Preliminary evaluation of the usefulness of determination of apolipoprotein B. cholesterol and VLDL triglyceride concentrations in the early diagnosis of type IV hyperlipoproteinemia].
Bobilewicz D; Kotlicka J; Grajnert K
Pol Tyg Lek; 1981 Mar; 36(9):325-6. PubMed ID: 7267451
[No Abstract] [Full Text] [Related]
16. [Familial hypercholesterolemia. Study of a family].
Ahumada-Ayala M; Núñez-Pulache A; Lozano-Castañeda O; Rull JA; Valles VE; Wong B
Rev Invest Clin; 1984; 36(3):269-75. PubMed ID: 6515160
[No Abstract] [Full Text] [Related]
17. In vivo platelet activity and lipoprotein patterns in coronary artery disease.
Goubran F; Maklady F; Saad M; el-Ashry M
Wien Klin Wochenschr; 1986 Apr; 98(7):209-11. PubMed ID: 3705598
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
[No Abstract] [Full Text] [Related]
19. [Long-term effects of a glycosaminoglycan on plasma lipids].
Avogaro P; Bittolo-Bon G; Alessandrini P
Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
[No Abstract] [Full Text] [Related]
20. [Rapid changes in blood lipid parameters induced by glucuronyl glucosamine glycan sulfate in obese diabetic and hyperlipidemia patients].
Ferlito S; La Spina E; Fichera C; Cultrera E; Patanè M; Ciulla P
Arch Sci Med (Torino); 1982; 139(4):441-8. PubMed ID: 7168636
[No Abstract] [Full Text] [Related]
[Next] [New Search]
